LGC Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:LGC Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013290
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
LGC Ltd (LGC) formerly LGC (Teddington) Limited, is a life sciences measurement and testing company which offers reference materials, genomics solutions and analytical testing products and services. Its products portfolio includes AutoGen, DNA extraction instrumentation, DNA extraction kits, Douglas scientific, genotyping chemistry, genotyping instruments, genotyping libraries and others. The company provides services such as genotyping, consultancy, consumer product testing, digital forensic investigation, DNA and RNA extraction services; DNA sequencing, drug and alcohol testing; drug development services, food and agricultural analytical services and others. The company caters to agrigenomics, forensic science, food, government and academia; human genomics, pharma and healthcare and sports sectors. It has operations across the US, Europe, Africa and Asia regions. LGC is headquartered in Teddington, Middlesex, the UK.

LGC Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
LGC Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
LGC Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
LGC Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
LGC Ltd, Medical Devices Deals, 2011 to YTD 2017 8
LGC Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
LGC Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
LGC Genomics To Acquire Bioanalytical Sciences Business Of Quotient BioResearch 10
Private Equity 11
KKR to Acquire LGC from Bridgepoint 11
Partnerships 12
EnviroLogix Enters Into Distribution Agreement With Douglas Scientific 12
Link Technologies Enters Into Distribution Agreement With GeneDesign 13
ChromaDex Enters Into Distribution Agreement With LGC Standards For LoGiCal Reference Standards 14
EnviroLogix Enters Into Co-Development Agreement With Douglas Scientific 15
Life Technologies Enters Into Co-Marketing Agreement With Douglas Scientific 16
Licensing Agreements 17
LGC Enters into Licensing Agreement with Keygene 17
Biosearch Technologies Enters Into Licensing Agreement With Rutgers University For turboFISH Technology 18
Biosearch Technologies Extends Licensing Agreement With University Of Medicine And Dentistry Of New Jersey For Stellaris RNA FISH Technology 19
Biosearch Technologies Enters Into Licensing Agreement With University of Medicine and Dentistry of New Jersey For Nucleic Acid Probe Technology 20
Acquisition 21
LGC Acquires Axolabs 21
LGC to Acquire Biosearch Technologies 22
Biosearch Technologies Acquires Majority Stake In LightSpeed Genomics 23
Management Of Axolabs Acquires The Company 24
LGC Acquires KBioscience 25
LGC Ltd – Key Competitors 26
LGC Ltd – Key Employees 27
LGC Ltd – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Joint Venture 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
LGC Ltd, Pharmaceuticals & Healthcare, Key Facts, 2015 2
LGC Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
LGC Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
LGC Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
LGC Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
LGC Ltd, Medical Devices Deals, 2011 to YTD 2017 8
LGC Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
LGC Genomics To Acquire Bioanalytical Sciences Business Of Quotient BioResearch 10
KKR to Acquire LGC from Bridgepoint 11
EnviroLogix Enters Into Distribution Agreement With Douglas Scientific 12
Link Technologies Enters Into Distribution Agreement With GeneDesign 13
ChromaDex Enters Into Distribution Agreement With LGC Standards For LoGiCal Reference Standards 14
EnviroLogix Enters Into Co-Development Agreement With Douglas Scientific 15
Life Technologies Enters Into Co-Marketing Agreement With Douglas Scientific 16
LGC Enters into Licensing Agreement with Keygene 17
Biosearch Technologies Enters Into Licensing Agreement With Rutgers University For turboFISH Technology 18
Biosearch Technologies Extends Licensing Agreement With University Of Medicine And Dentistry Of New Jersey For Stellaris RNA FISH Technology 19
Biosearch Technologies Enters Into Licensing Agreement With University of Medicine and Dentistry of New Jersey For Nucleic Acid Probe Technology 20
LGC Acquires Axolabs 21
LGC to Acquire Biosearch Technologies 22
Biosearch Technologies Acquires Majority Stake In LightSpeed Genomics 23
Management Of Axolabs Acquires The Company 24
LGC Acquires KBioscience 25
LGC Ltd, Key Competitors 26
LGC Ltd, Key Employees 27
LGC Ltd, Other Locations 28
LGC Ltd, Subsidiaries 28
LGC Ltd, Joint Venture 29

★海外企業調査レポート[LGC Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Taylor Communications Inc:企業の戦略的SWOT分析
    Taylor Communications Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • BOC Aviation Limited (2588):企業の財務・戦略的SWOT分析
    BOC Aviation Limited (2588) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • International Flavors & Fragrances Inc.:企業の戦略・SWOT・財務分析
    International Flavors & Fragrances Inc. - Strategy, SWOT and Corporate Finance Report Summary International Flavors & Fragrances Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Essel Propack Limited:戦略・SWOT・企業財務分析
    Essel Propack Limited - Strategy, SWOT and Corporate Finance Report Summary Essel Propack Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • AMW GmbH:医療機器:M&Aディール及び事業提携情報
    Summary AMW GmbH (AMW) is a pharmaceutical company that develops and manufactures drug delivery systems for treatment in the areas of oncology, neurology, dermatology and pain. The company designs and develops novel transdermal drug delivery systems, microchip controlled patches and biodegradable su …
  • Voyager Therapeutics Inc (VYGR):企業の財務・戦略的SWOT分析
    Summary Voyager Therapeutics Inc (Voyager) is a gene therapy company that discovers, develops and commercializes therapies to treat severe neurological diseases. It is evaluating VY-AADC program for the treatment of advanced Parkinson’s disease; VY-SOD102 against monogenic amyotrophic lateral sclero …
  • Covalon Technologies Ltd (COV)-医療機器分野:企業M&A・提携分析
    Summary Covalon Technologies Ltd (Covalon) is a researcher, developer and commercialization of medical devices and healthcare technologies. The company offers advanced wound solutions, infection prevention products and perioperative care products. Covalon offers wound care products such as collagen …
  • TOR Minerals International Inc (TORM):企業の財務・戦略的SWOT分析
    Summary TOR Minerals International Inc (TOR) is a chemical company that manufactures and distributes mineral and pigment products. The company provides products such as optiload, aluprem, haltex, and others. It also offers alumina trihydrate and boehmite halogen-free flame retardant and smoke suppre …
  • Powell Industries Inc (POWL):企業の財務・戦略的SWOT分析
    Powell Industries Inc (POWL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • First Bank of Nigeria Ltd:企業の戦略・SWOT・財務情報
    First Bank of Nigeria Ltd - Strategy, SWOT and Corporate Finance Report Summary First Bank of Nigeria Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Matthews International Corp (MATW):企業の財務・戦略的SWOT分析
    Matthews International Corp (MATW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Mercy Health:企業の戦略的SWOT分析
    Mercy Health - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • MicroPort Scientific Corp (853):医療機器:M&Aディール及び事業提携情報
    Summary MicroPort Scientific Corp (MicroPort) a subsidiary of Otsuka Medical Devices Co Ltd is a medical device company which develops, manufactures and markets cardiovascular treatment devices. The company provides products such as cardiovascular devices, orthopedic devices, endovascular devices, e …
  • Merit Medical Systems Inc (MMSI):企業の製品パイプライン分析2018
    Summary Merit Medical Systems, Inc. (Merit Medical) offers a wide range of single-use medical devices for interventional and diagnostic procedures. The company’s products include inflation devices and accessories, diagnostic and therapeutic catheters, diagnostic and hydrophilic products, thrombolyti …
  • Sangamo Therapeutics Inc (SGMO)-製薬・医療分野:企業M&A・提携分析
    Summary Sangamo Therapeutics Inc (Sangamo), formerly Sangamo BioSciences Inc, is a clinical stage biopharmaceutical company which focuses on the research and development and commercialization of engineered DNA-binding proteins (ZFPs) for gene regulation and therapeutic genome editing. The company is …
  • GeoVax Labs Inc (GOVX):製薬・医療:M&Aディール及び事業提携情報
    Summary GeoVax Labs Inc (GeoVax) develops human vaccines for diseases caused by human immunodeficiency virus (HIV), cancer and other infectious diseases using Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) vaccine platform. The company’s vaccine development programs focus on HIV, Zika virus …
  • U.S. HealthWorks Medical Group:企業のM&A・事業提携・投資動向
    U.S. HealthWorks Medical Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's U.S. HealthWorks Medical Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Taisho Pharmaceutical Holdings Co Ltd:企業の戦略・SWOT・財務情報
    Taisho Pharmaceutical Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Taisho Pharmaceutical Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Biosynex SA (ALBIO):製薬・医療:M&Aディール及び事業提携情報
    Summary Biosynex SA (Biosynex), formerly All Diag Sarl is an in-vitro diagnostic company that manufactures, research, and develops rapid diagnostic tests. The company offers rapid diagnostic kits for diagnostic applications; and designing, self-measurement, and distributing thermometers. It offers t …
  • Targovax ASA (TRVX):製薬・医療:M&Aディール及び事業提携情報
    Summary Targovax ASA (Targovax) is a developer and commercializer of immunotherapies for the treatment of cancer patients. The company’s lead candidates include TG0, a peptide-based therapeutic anti-cancer vaccine under development for pancreatic cancer; and ONCOS-102 is an adenovirus-based pipeline …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆